021-51111890
购物车（）
sales@molnova.cn
Serdemetan
CAS No. 881202-45-5
Serdemetan ( JNJ 26854165 | JNJ26854165 | JNJ-26854165 )
产品货号. M16390 CAS No. 881202-45-5
Serdemetan (JNJ 26854165) 是一种新型抗癌化合物，可抑制 E3 连接酶 HDM2 的功能。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥313 | 有现货 |
|
| 5MG | ￥511 | 有现货 |
|
| 10MG | ￥805 | 有现货 |
|
| 25MG | ￥1516 | 有现货 |
|
| 50MG | ￥2716 | 有现货 |
|
| 100MG | ￥3762 | 有现货 |
|
| 500MG | ￥7938 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥560 | 有现货 |
|
生物学信息
-
产品名称Serdemetan
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Serdemetan (JNJ 26854165) 是一种新型抗癌化合物，可抑制 E3 连接酶 HDM2 的功能。
-
产品描述Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM; induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells; demonstrates radiosensitizing activity in vitro and in tumor xenografts.Lung Cancer Phase 1 Discontinued.
-
体外实验——
-
体内实验——
-
同义词JNJ 26854165 | JNJ26854165 | JNJ-26854165
-
通路Apoptosis
-
靶点MDM2-p53
-
受体HDM2|Mdm2|p53
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number881202-45-5
-
分子量328.4103
-
分子式C21H20N4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESC1(NCCC2=CNC3=C2C=CC=C3)=CC=C(NC4=CC=NC=C4)C=C1
-
化学全称1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kojima K, et al. Mol Cancer Ther. 2010 Sep;9(9):2545-57.
2. Tabernero J, et al. Clin Cancer Res. 2011 Oct 1;17(19):6313-21.
3. Chargari C, et al. Cancer Lett. 2011 Dec 22;312(2):209-18.
4. Jones RJ, et al. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92.
